Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Zohren F"" wg kryterium: Wszystkie pola


Tytuł :
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.
Autorzy :
Sternberg CN; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Fizazi K; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Saad F; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Shore ND; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
De Giorgi U; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Penson DF; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Ferreira U; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Efstathiou E; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Madziarska K; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Kolinsky MP; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Cubero DIG; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Noerby B; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Zohren F; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Lin X; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Modelska K; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Sugg J; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Steinberg J; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Hussain M; From the Englander Institute for Precision Medicine, Weill Cornell Medicine, New York (C.N.S.); the University of Paris Saclay, Villejuif, France (K.F.); the University of Montreal Hospital Center, Montreal (F.S.), and Cross Cancer Institute, University of Alberta, Edmonton (M.P.K.) - both in Canada; the Carolina Urologic Research Center, Myrtle Beach, SC (N.D.S.); Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy (U.D.); Vanderbilt University, Nashville (D.F.P.); the State University of Campinas (Unicamp), Campinas (U.F.), and the ABC Foundation School of Medicine, Santo André (D.I.G.C.) - both in Brazil; M.D. Anderson Cancer Center, Houston (E.E.); Wroclaw Medical University, Wroclaw, Poland (K. Madziarska); Sygehus Lillebælt, Vejle, Denmark (B.N.); Pfizer, La Jolla (F.Z., X.L.), and Pfizer, San Francisco (K. Modelska) - both in California; and Astellas Pharma, Northbrook (J. Sugg, J. Steinberg), and the Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago (M.H.) - both in Illinois.
Pokaż więcej
Corporate Authors :
PROSPER Investigators
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jun 04; Vol. 382 (23), pp. 2197-2206. Date of Electronic Publication: 2020 May 29.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Adenocarcinoma/*drug therapy
Androgen Antagonists/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Phenylthiohydantoin/*analogs & derivatives
Prostatic Neoplasms, Castration-Resistant/*drug therapy
Adenocarcinoma/mortality ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Double-Blind Method ; Humans ; Kallikreins/blood ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Phenylthiohydantoin/adverse effects ; Phenylthiohydantoin/therapeutic use ; Placebos ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms, Castration-Resistant/mortality ; Survival Analysis
Czasopismo naukowe
Tytuł :
Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia.
Autorzy :
Zohren, F. Fabian.Zohren@med.uni-duesseldorf.de
Czibere, A.
Bruns, I.
Fenk, R.
Schroeder, T.
Gräf, T.
Haas, R.
Kobbe, G.
Pokaż więcej
Źródło :
Bone Marrow Transplantation. Dec2009, Vol. 44 Issue 12, p785-792. 8p. 4 Charts, 1 Graph.
Czasopismo naukowe
Tytuł :
Bendamustine in patients with relapsed or refractory multiple myeloma
Autorzy :
Michael M
Bruns I
Bölke E
Zohren F
Czibere A
Safaian N N
Neumann F
Haas R
Kobbe G
Fenk R
Pokaż więcej
Temat :
Bendamustine
multiple myeloma
relapsed/refractory
Medicine
Źródło :
European Journal of Medical Research, Vol 15, Iss 1, p 13 (2010)
Opis pliku :
electronic resource
Relacje :
http://www.eurjmedres.com/content/15/1/13; https://doaj.org/toc/2047-783X
Dostęp URL :
https://doaj.org/article/297f98c68bce4c4ea8e3545b3a0be363
Czasopismo naukowe
Tytuł :
Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Autorzy :
Zohren, F. zohren@bcm.tmc.edu
Schroeder, T.
Czibere, A.
Fenk, R.
Bruns, I.
Kondakci, M.
Saure, C.
Haas, R.
Kobbe, G.
Pokaż więcej
Źródło :
Bone Marrow Transplantation. May2011, Vol. 46 Issue 5, p747-755. 9p. 3 Charts, 4 Graphs.
Czasopismo naukowe
Tytuł :
Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation.
Autorzy :
Schroeder, T
Czibere, A
Platzbecker, U
Bug, G
Uharek, L
Luft, T
Giagounidis, A
Zohren, F
Bruns, I
Wolschke, C
Rieger, K
Fenk, R
Germing, U
Haas, R
Kröger, N
Kobbe, G
Pokaż więcej
Temat :
AZACITIDINE
LYMPHOCYTES
SALVAGE therapy
CANCER treatment
ACUTE myeloid leukemia treatment
STEM cell transplantation
THERAPEUTICS
Źródło :
Leukemia (08876924); Jun2013, Vol. 27 Issue 6, p1229-1235, 7p, 1 Diagram, 4 Charts, 1 Graph
Czasopismo naukowe
Tytuł :
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.
Autorzy :
Moore KN; Stephenson Oklahoma Cancer Center, University of Oklahoma, Norman, Oklahoma, USA.
Bauer TM; Sarah Cannon Research Institute/Tennessee Oncology, PPLC, Nashville, Tennessee, USA.
Falchook GS; Denver Drug Development Unit, Sarah Cannon Research Institute at HealthONE, Denver, Colorado, USA.
Chowdhury S; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Patel C; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Neuwirth R; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Enke A; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Zohren F; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, Massachusetts, USA.
Patel MR; Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida, USA.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2018 Feb 01; Vol. 3 (2), pp. e000291. Date of Electronic Publication: 2018 Feb 01 (Print Publication: 2018).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Combining Azacitidine (Vidaza®, Aza) and Donor Lymphocyte Infusions (DLI) as First Salvage Treatment in Patients (PTS) With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS) Relapsing After Allogeneic Hematopoietic Stem Cell Transplantation (allo-SCT): Interim-Analysis From the Azarela-Trial (NCT-00795548)
Autorzy :
Schroeder, T.
Czibere, A.G.
Kröger, N.
Platzbecker, U.
Bug, G.
Uharek, L.
Luft, T.
Bruns, I.
Zohren, F.
Wolschke, C.
Fenk, R.
Haas, R.
Kobbe, G.
Pokaż więcej
Temat :
Transplantation
Hematology
Źródło :
Biology of Blood and Marrow Transplantation. 17
Tytuł :
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies.
Autorzy :
Juric D; Massachusetts General Hospital, Boston, Massachusetts. .
de Bono JS; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
LoRusso PM; Yale University, New Haven, Connecticut.
Nemunaitis J; Mary Crowley Cancer Research Center, Dallas, Texas.
Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
Kwak EL; Massachusetts General Hospital, Boston, Massachusetts.
Macarulla Mercadé T; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Geuna E; Investigative Clinical Oncology, Fondazione Del Piemonte Per L'Oncologia, Candiolo Cancer Institute, Candiolo, Italy.
Jose de Miguel-Luken M; The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom.
Patel C; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Kuida K; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Sankoh S; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Westin EH; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Zohren F; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Shou Y; Millennium Pharmaceuticals, Inc., Cambridge, Massachusetts, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Tabernero J; Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Sep 01; Vol. 23 (17), pp. 5015-5023. Date of Electronic Publication: 2017 May 10.
Typ publikacji :
Clinical Trial, Phase I; Journal Article
MeSH Terms :
Benzoxazoles/*administration & dosage
Class I Phosphatidylinositol 3-Kinases/*genetics
Imidazoles/*administration & dosage
Morpholines/*administration & dosage
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Pyridines/*administration & dosage
Adult ; Aged ; Aged, 80 and over ; Benzoxazoles/adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Imidazoles/adverse effects ; Male ; Middle Aged ; Morpholines/adverse effects ; Neoplasm Staging ; Neoplasms/genetics ; Neoplasms/pathology ; Protein Kinase Inhibitors/adverse effects ; Pyridines/adverse effects
Czasopismo naukowe
Tytuł :
Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
Autorzy :
Schuler E; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany. .
Wagner-Drouet EM; Department of Hematology, Oncology, Pneumology, Medical Clinic III, UCT Johannes Gutenberg-University Mainz, Mainz, Germany.
Ajib S; Department of Medicine II, Goethe University, Frankfurt am Main, Germany.
Bug G; Department of Medicine II, Goethe University, Frankfurt am Main, Germany.
Crysandt M; Department of Hematology, Oncology, Hemostasiology and Stem Cell Transplantation, Medical Clinic IV, University Hospital RWTH Aachen, Aachen, Germany.
Dressler S; Bone Marrow Transplantation Unit, Medical Clinic 5, Nürnberg, Germany.
Hausmann A; Department of Hematology, Oncology, Immunology, Palliative Care, Munich Clinic Schwabing, Munich, Germany.
Heidenreich D; Medical Clinic III, University Medicine Mannheim, Mannheim, Germany.
Hirschbühl K; Department of Hematology and Oncology, Medical Clinic II, University Hospital Augsburg, Augsburg, Germany.
Hoepting M; Medical Clinic III, University Medicine Regensburg, Regensburg, Germany.
Jost E; Department of Hematology, Oncology, Hemostasiology and Stem Cell Transplantation, Medical Clinic IV, University Hospital RWTH Aachen, Aachen, Germany.
Kaivers J; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
Klein S; Medical Clinic III, University Medicine Mannheim, Mannheim, Germany.
Koldehoff M; Clinic for Bone Marrow Transplantation, University Hospital Essen, Essen, Germany.
Kordelas L; Clinic for Bone Marrow Transplantation, University Hospital Essen, Essen, Germany.
Kriege O; Department of Hematology, Oncology, Pneumology, Medical Clinic III, UCT Johannes Gutenberg-University Mainz, Mainz, Germany.
Müller LP; Department of Internal Medicine IV, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Rautenberg C; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
Schaffrath J; Department of Internal Medicine IV, University Hospital Halle, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Schmid C; Department of Hematology and Oncology, Medical Clinic II, University Hospital Augsburg, Augsburg, Germany.
Wolff D; Medical Clinic III, University Medicine Regensburg, Regensburg, Germany.
Haas R; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
Bornhäuser M; Department of Internal Medicine I, University Hospital Carl Gustav Carus at the Technische Universität, Dresden, Germany.
Schroeder T; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
Kobbe G; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Medical Faculty, Heinrich Heine University, Moorenstr. 5, 40225, Düsseldorf, Germany.
Pokaż więcej
Corporate Authors :
German Cooperative Transplant Study Group
Źródło :
Annals of hematology [Ann Hematol] 2021 Apr; Vol. 100 (4), pp. 959-968. Date of Electronic Publication: 2020 Nov 16.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Salvage Therapy*/adverse effects
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Leukemia, Myeloid, Acute/*drug therapy
Myelodysplastic Syndromes/*drug therapy
Allografts ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/administration & dosage ; Azacitidine/adverse effects ; Azacitidine/pharmacology ; Bridged Bicyclo Compounds, Heterocyclic/administration & dosage ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Combined Modality Therapy ; DNA Methylation/drug effects ; Decitabine/administration & dosage ; Decitabine/adverse effects ; Decitabine/pharmacology ; Drug Evaluation ; Febrile Neutropenia/blood ; Febrile Neutropenia/chemically induced ; Germany/epidemiology ; Humans ; Immunosuppressive Agents/adverse effects ; Immunosuppressive Agents/therapeutic use ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/therapy ; Leukocyte Count ; Myelodysplastic Syndromes/therapy ; Recurrence ; Retrospective Studies ; Sulfonamides/administration & dosage ; Sulfonamides/adverse effects ; Thrombocytopenia/blood ; Thrombocytopenia/chemically induced ; Transplantation Conditioning ; Tumor Lysis Syndrome/etiology
Czasopismo naukowe
Tytuł :
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenström's macroglobulinemia.
Autorzy :
Ghobrial IM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Siegel DS; John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey.
Vij R; Division of Hematology and Oncology, Washington University School of Medicine, St. Louis, Missouri.
Berdeja JG; Sarah Cannon Research Institute, Nashville, Tennessee.
Richardson PG; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Neuwirth R; Global Biostatistics, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited.
Patel CG; Clinical Pharmacology, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited.
Zohren F; Oncology Clinical Research, Millennium Pharmaceuticals, Inc, Cambridge, Massachusetts, USA, a Wholly Owned Subsidiary of Takeda Pharmaceutical Company Limited.
Wolf JL; Department of Medicine, University of California San Francisco, San Francisco, California.
Pokaż więcej
Źródło :
American journal of hematology [Am J Hematol] 2016 Jun; Vol. 91 (4), pp. 400-5.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Agents/*therapeutic use
Benzoxazoles/*therapeutic use
Lymphoma, Non-Hodgkin/*drug therapy
Multiple Myeloma/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Waldenstrom Macroglobulinemia/*drug therapy
Administration, Oral ; Aged ; Aged, 80 and over ; Antineoplastic Agents/pharmacology ; Benzoxazoles/pharmacology ; Drug Monitoring ; Female ; Humans ; Lymphoma, Non-Hodgkin/diagnosis ; Male ; Maximum Tolerated Dose ; Mechanistic Target of Rapamycin Complex 1 ; Mechanistic Target of Rapamycin Complex 2 ; Middle Aged ; Multiple Myeloma/diagnosis ; Multiprotein Complexes/antagonists & inhibitors ; Neoplasm Grading ; Neoplasm Staging ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology ; Recurrence ; Retreatment ; TOR Serine-Threonine Kinases/antagonists & inhibitors ; Treatment Outcome ; Waldenstrom Macroglobulinemia/diagnosis
Czasopismo naukowe
Tytuł :
5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis.
Autorzy :
Czibere, A.
Bruns, I.
Kröger, N.
Platzbecker, U.
Lind, J.
Zohren, F.
Fenk, R
Germing, U.
Schröder, T.
Gräf, T.
Haas, R.
Kobbe, G.
Pokaż więcej
Temat :
MYELODYSPLASTIC syndromes
BONE marrow diseases
ACUTE myeloid leukemia
HEMATOPOIETIC stem cells
LEUCOCYTES
CLINICAL trials
Źródło :
Bone Marrow Transplantation; May2010, Vol. 45 Issue 5, p872-876, 5p, 1 Chart, 1 Graph
Czasopismo naukowe
Tytuł :
Prognostic value of circulating Bcl-2/IgH levels in patients with follicular lymphoma receiving first-line immunochemotherapy.
Autorzy :
Zohren F; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Bruns I; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Pechtel S; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Schroeder T; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Fenk R; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Czibere A; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Maschmeyer G; Klinikum Ernst von Bergmann, Potsdam, Germany;
Kofahl-Krause D; Medizinische Hochschule Hannover, Hannover, Germany;
Niederle N; Klinikum Leverkusen, Leverkusen, Germany;
Heil G; Kreiskrankenhaus Lüdenscheid, Lüdenscheid, Germany;
Losem C; Onkologische Praxis Neuss, Neuss, Germany;
Welslau M; Onkologische Praxis Aschaffenburg, Aschaffenburg, Germany;
Brugger W; Schwarzwald-Baar-Klinikum Villingen, Villingen, Germany; and.
Germing U; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Kronenwett R; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Barth J; Justus-Liebig-Universität, Giessen, Germany.
Rummel MJ; Justus-Liebig-Universität, Giessen, Germany.
Haas R; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Kobbe G; University Hospital Düsseldorf, Heinrich-Heine-Universität, Düsseldorf, Germany;
Pokaż więcej
Źródło :
Blood [Blood] 2015 Sep 17; Vol. 126 (12), pp. 1407-14. Date of Electronic Publication: 2015 Aug 03.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Follicular/*blood
Lymphoma, Follicular/*drug therapy
Oncogene Proteins, Fusion/*blood
Aged ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Bendamustine Hydrochloride/administration & dosage ; Bendamustine Hydrochloride/therapeutic use ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/therapeutic use ; Disease-Free Survival ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Follicular/diagnosis ; Lymphoma, Follicular/genetics ; Male ; Middle Aged ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Prognosis ; Rituximab/administration & dosage ; Rituximab/therapeutic use ; Vincristine/administration & dosage ; Vincristine/therapeutic use
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies